Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Reproduction of any article requires authorization.
Recently, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA),China's First Allogeneic Universal Off-the-Shelf iNKT Cell Injection (GKL-006Allo Injection) New Drug Clinical Trial (IND) Approved by the National Medical Products Administration (NMPA); Indications are for locally advanced or metastatic solid tumors that have failed standard treatment. This is the fourth IND approval for Beijing Gene Key Life Technology Co., Ltd., markingThe First in ChinaAllogeneic universal off-the-shelf iNKT cell therapy product officially enters the registrational clinical stage, offering patients a more convenient and accessible treatment option.As the world's first company to develop a series of iNKT cell pipeline products, Gene Key Life Technology's breakthrough in this field is no accident. Previously, it had successively obtainedThree Key IND Approvals: The world's first iNKT cell injection (GKL-006 injection) for "unresectable primary hepatocellular carcinoma," "prevention of high-risk recurrence after radical resection in patients with primary hepatocellular carcinoma," and "advanced pancreatic cancer." The approval of GKL-006Allo injection further enhances its pipeline layout of "solid tumor treatment + recurrence prevention" and highlights its globally leading position in iNKT cell technology.From the perspective of technical advantages, iNKT cells (invariant Natural Killer T Cells) are truly "versatile players" in the immune field — combining the specific killing ability of T cells with the rapid response capability of NK cells. They can overcome the immunosuppressive environment of solid tumors and are not restricted by HLA (avoiding graft-versus-host disease). Relying on its proprietary intellectual property rights for an iNKT cell hyperexpansion platform and unique subpopulation distribution technology, Beijing Gene Key Life Technology Co., Ltd has achieved large-scale, high-quality preparation of iNKT cells. Previously, safety and efficacy were validated in the treatment of primary liver cancer. The current clinical advancement of this universal product will further reduce treatment costs, shorten patient waiting times, and drive cell therapy from "customization" towards "universal accessibility."Currently, globally, iNKT cell therapy has gained increasing attention and investment from more and more research teams and international biopharmaceutical companies. Relatively speaking, there are more iNKT cell therapy developers outside China, such as Mink Therapeutics, Arovella Therapeutics, Kite & Appia Bio, etc. Among them, Mink Therapeutics has one iNKT cell therapy product in Phase I/II clinical trials and four CAR-iNKT cell therapy products in preclinical development; Arovella Therapeutics has four CAR-iNKT products in preclinical development; Kite & Appia Bio has two CAR-iNKT therapies in preclinical development.
